Shares of Kaleido Biosciences, Inc. (NASDAQ:KLDO) have been given a consensus recommendation of “Hold” by the seven brokerages that are presently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating on the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $17.88.
Several research analysts have issued reports on KLDO shares. JMP Securities started coverage on shares of Kaleido Biosciences in a report on Wednesday, December 23rd. They issued an “outperform” rating and a $22.00 target price for the company. Chardan Capital lifted their target price on shares of Kaleido Biosciences from $10.00 to $17.50 and gave the stock a “buy” rating in a report on Thursday, January 14th. Morgan Stanley lifted their target price on shares of Kaleido Biosciences from $8.00 to $13.00 and gave the stock an “equal weight” rating in a report on Tuesday, January 19th. Piper Sandler started coverage on shares of Kaleido Biosciences in a report on Tuesday, February 9th. They issued an “overweight” rating and a $19.00 target price for the company. Finally, Zacks Investment Research cut shares of Kaleido Biosciences from a “buy” rating to a “hold” rating in a report on Wednesday, January 6th.
In related news, major shareholder Ventures Fund Iv Gene Flagship acquired 215,000 shares of the firm’s stock in a transaction dated Monday, February 8th. The stock was purchased at an average cost of $11.50 per share, with a total value of $2,472,500.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 10.00% of the stock is owned by insiders.
Several institutional investors and hedge funds have recently added to or reduced their stakes in KLDO. FMR LLC purchased a new position in shares of Kaleido Biosciences during the first quarter valued at approximately $25,143,000. BlackRock Inc. increased its holdings in Kaleido Biosciences by 75.9% during the fourth quarter. BlackRock Inc. now owns 938,631 shares of the company’s stock valued at $8,541,000 after buying an additional 404,988 shares during the last quarter. Charles Schwab Investment Management Inc. increased its holdings in Kaleido Biosciences by 136.6% during the third quarter. Charles Schwab Investment Management Inc. now owns 95,414 shares of the company’s stock valued at $1,057,000 after buying an additional 55,094 shares during the last quarter. First Trust Advisors LP increased its holdings in Kaleido Biosciences by 259.4% during the third quarter. First Trust Advisors LP now owns 39,551 shares of the company’s stock valued at $438,000 after buying an additional 28,546 shares during the last quarter. Finally, Nuveen Asset Management LLC increased its holdings in Kaleido Biosciences by 95.1% during the second quarter. Nuveen Asset Management LLC now owns 56,939 shares of the company’s stock valued at $423,000 after buying an additional 27,759 shares during the last quarter. 79.91% of the stock is owned by hedge funds and other institutional investors.
NASDAQ:KLDO traded down $0.48 during mid-day trading on Tuesday, hitting $9.77. 18,786 shares of the company’s stock were exchanged, compared to its average volume of 329,716. Kaleido Biosciences has a one year low of $2.82 and a one year high of $20.50. The business has a fifty day moving average price of $12.15 and a 200 day moving average price of $8.89. The company has a market cap of $351.54 million, a PE ratio of -3.67 and a beta of 0.02.
Kaleido Biosciences Company Profile
Kaleido Biosciences, Inc, a clinical-stage healthcare company, develops microbiome metabolic therapies. The company offers product candidates for the treatment of urea cycle disorders; hepatic encephalopathy; infections caused by multi-drug resistant bacteria; cardiometabolic and liver diseases; and immune oncology.
See Also: What is a growth and income fund?
Receive News & Ratings for Kaleido Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kaleido Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.